Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions a gain of 26.7% for the S&P Composite 1500. In 2021, the S&P Pharmaceuticals Index returned a gain of 21.8%, vs. a 13.6% decline for the S&P Composite 1500 Index. Year to date through June 3, the S&P Pharmaceuticals Index was up 1.5% vs. While this provides uncertainty in the long-term, it is unlikely that legislation will get passed in the near future due to more pressing issues in the political agenda. Lowering drug prices continues to be a bipartisan issue as both parties aim to offer Americans more affordable prices. Despite this, policy risks are on the rise. Generic drug makers are expected to continue to struggle due to lower-cost emerging market competition. Recent FDA recommendations, such as approval for a fourth booster dose for those aged 50 or older, suggests we may be moving in this direction. If that were to happen, it would prove to be very lucrative for pharmaceutical companies, as it would generate recurring sales. Should COVID-19 variants continue to arise getting a COVID-19 vaccine could become a seasonal phenomenon, much like the flu vaccine. COVID-19 therapies, oncology and immunology are essential aspects of pharmaceutical companies. The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives and improved medical utilization. Horizon Therapeutics PLC does not currently pay a dividend. Analysts expect adjusted earnings to reach $5.123 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was -6.0%. Horizon Therapeutics PLC’s trailing 12-month revenue is $3.6 billion with a 10.4% profit margin. Latest Horizon Therapeutics PLC Stock NewsĪs of July 28, 2023, Horizon Therapeutics PLC had a $22.8 billion market capitalization, putting it in the 93rd percentile of companies in the Pharmaceuticals industry.Ĭurrently, Horizon Therapeutics PLC’s price-earnings ratio is 63.0. Read on to find out how ( HZNP) grades on certain investment factors and determine whether it meets your investment needs. Learn more about whether Horizon Therapeutics PLC is a good stock to buy or sell based on recent news as well as its key financial metrics.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |